Roche Group posts strong sales growth in the first quarter

Group sales increase 6% at CER to 11.6 billion Swiss francs; Pharmaceuticals sales rise 7% to 9.2 billion Swiss francs, driven by cancer medicines and Tamiflu; Successful launches of Kadcyla and Perjeta strengthen HER2-positive breast cancer franchise
Source: Roche Media News - Category: Pharmaceuticals Source Type: news